ALVAL.PA Valbiotis SAS

Consumer Defensive Biotechnology Euronext Paris
0.6400 EUR
Close of Nov 6, 2026
0.4860 1.27
Market cap
EUR 22.7M
P/E
-
P/B
1.81x
ROE
-107.6%
Dividend yield
-
Fundamental score
0.5/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALVAL.PA undervalued?

Graham number

The Graham number of Valbiotis SAS cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Valbiotis SAS fundamental analysis

2 of 11 checks passed

ROE 0/2

Negative ROE (-89.04%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

ROA 0/2

The stock's ROA (-46.87%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

PBV 0/2

The stock's elevated P/BV ratio (4.63x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

DER 1/2

The stock maintains a fair debt to equity ratio (54%), indicating a reasonable balance between the money it owes and the ownership it possesses.

Revenue Growth 0/2

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

Net Profit Growth 0/2

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

Assets Growth 0/2

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

Graham Number 1/1

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

Dividend Growth 0/2

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Dividend 0/2

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

Buffet Intrinsic Value 0/1

The company's stock presents a potential concern as it appears overvalued (-1) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Valbiotis SAS stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Valbiotis SAS

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood p…

Full company profile